. Management of pregnancy in women with rheumatic diseases is affected by various factors. Active disease is associated with APOs 6 ; hence, DMARDs are required dur ing pregnancy to ensure control of maternal disease and satisfactory pregnancy outcomes. However, prescription of many DMARDs is complicated by safety concerns and evidence based guidelines are unable to provide reli able evidence based recommendations for all drugs [7] [8] [9] . Specific pregnancy concerns exist for various conditions that should be considered when discussing pregnancy planning and disease management with patients.
Conversations between clinicians and patients with rheumatic diseases are vital to ensure that the patient understands the potential effects of the timing of con ception (with respect to disease activity), of disease upon pregnancy and of pregnancy upon disease, and the potential need for medication alterations in relation to pregnancy and breastfeeding.
This Review focuses on pregnancy planning in patients with RA, SLE, psoriatic arthritis (PsA), spondylo arthritis, primary Sjögren syndrome or SSc. Pregnancy in patients with primary systemic vasculitis is rare; advice specific to this disease is beyond the scope of this article but it is managed in a similar manner to SLE.
Timing of pregnancy
Patients with inflammatory rheumatic diseases should conceive during a period of disease quiescence to reduce the risk of disease flare in pregnancy 6, 9, 10 . In patients with well controlled disease that lacks extra articular mani festations and organ dysfunction, a 3month period of disease control on stable medications compatible with pregnancy should suffice, but the precise duration of this period of quiescence is a matter of debate. In SLE, the risk of disease flare during pregnancy is increased in patients with active disease within 4-6 months before conception 11, 12 , in patients with active disease at con ception 13, 14 , and following discontinuation of hydroxy chloroquine (even when disease is quiescent) 15, 16 . EULAR recommends that 6-12 months of disease qui escence is needed before conception dependent on var ious maternal factors, such as degree of residual organ dysfunction 17 .
Effect of disease on pregnancy Fertility and parity. Patients with inflammatory rheumatic diseases have fewer children than other women 6, 18 . Explanations for this phenomenon include physical disability 19 , renal failure 20 , teratogenic med ications 21 , depression or fatigue, which can lead to
Intrauterine growth restriction (IUGR) . Reduced fetal growth resulting in an estimated weight below the 10th percentile for gestational age.
Stratifying management of rheumatic disease for pregnancy and breastfeeding reduced libido or sexual dysfunction in women 22 , and increasing maternal age associated with reduced ovar ian reserves and oocyte quality 23 (reviewed elsewhere 24 ). In particular, cyclophosphamide-induced gonadal toxicity is a substantial problem for patients with severe rheu matic disease 21, 24 , and strategies have been developed to safeguard against fertility loss before treatment with cytotoxic drugs 25 . These strategies include semen cryo preservation, embryo or oocyte cryopreservation, and the use of gonadotropin releasing hormone analogues or agonists to suppress ovarian function and utero ovarian blood flow in order to reduce exposure to gonadotoxic drugs such as cyclophosphamide. However, the use of gonadotropin releasing hormone analogues is contro versial and data from randomized trials of their use in patients receiving chemotherapy for different cancers are inconsistent 25 .
Risk of adverse pregnancy outcomes. An increased burden of APOs has been reported in various inflam matory rheumatic diseases, described below and in TaBle 1 . Various retrospective studies have shown that women with RA are at an increased risk of hyperten sive disorders of pregnancy (gestational hypertension and pre-eclampsia), IUGR, premature delivery, caesar ean delivery and increased length of hospital stay for pregnancy in population studies that included >3,500 patients with RA [26] [27] [28] [29] . Although a smaller retrospective cohort study (243 women with RA) also confirmed an increased risk of prematurity and caesarean section, an approximately 50% increased risk of hypertensive disorders of pregnancy and reduced fetal growth in patients with RA was not statistically significant com pared with population controls 30 . In other small (up to 150 patients) prospective studies of pregnancy in patients with RA, the risk of hypertensive disorders was increased in one study 31 , but not in two others 10, 32 . Overall, given the consistent finding of an increased risk of hypertensive disorders in RA pregnancy from large population studies it would seem prudent to counsel women with RA about this risk.
In SLE, several large (mostly retrospective) population based studies of a total of >15,000 pregnan cies in patients with SLE have identified an increased risk of hypertensive disorders of pregnancy, pre term labour and IUGR 14, [33] [34] [35] [36] . In addition, a meta analysis including studies published between 2001 and 2016 (includ ing 3,395 patients with SLE) confirmed an increased risk of a range of maternal and fetal APOs, including hypertension (relative risk (RR) 1.99), pre eclampsia (RR 1.91), pre term labour (RR 3.05), IUGR (RR 4.44) and small for gestational age (RR 1.69) 37 . High disease activity immediately before and dur ing pregnancy is clearly linked with APOs in RA and SLE 10, 38, 39 . A cohort study of pregnancy in patients with axial spondyloarthritis found an increased risk of APOs in these patients compared with healthy individuals as well as an association between active disease and preterm delivery 31 . The effect of other inflammatory rheumatic dis eases on pregnancy outcome is not well characterized. Pregnancy in PsA does not seem to be associated with APOs 40, 41 . Case-control studies have shown an increase in the rates of spontaneous abortion, preterm deliveries and caesarean section in pregnancies in women with pri mary Sjögren syndrome compared with those in healthy individuals 42 . A high frequency of pre term births and small full term infants has been shown to occur in patients with SSc, with no difference in the frequency of miscarriage and neonatal survival compared with healthy individuals 43 .
Effect of pregnancy on disease Remission and relapse in pregnancy. Reports of improvement in disease activity in as many as 90% of RA pregnancies come mostly from retrospective studies that do not reflect current practice, as the use of biologic therapies now enables many women with severe disease to become pregnant 6, 44 . Studies using validated measures of disease activity, such as the 28joint Disease Activity Score for RA, found less convincing evidence that preg nancy reduces disease activity, with only 48-60% of women with active RA showing signs of reduced dis ease activity during pregnancy and 39-50% having a disease flare within 6 months post partum 45 . The effect of pregnancy on SLE disease activity is unclear, as some studies have reported no increased risk of SLE flares during pregnancy, compared with non pregnant patients with SLE 13, 46, 47 , whereas other studies show that pregnancy is associated with an increased SLE flare rate [48] [49] [50] . These results are conflict ing, possibly because of small cohort sizes and the use of varying methodologies to assess disease activity and define disease flares, but a systematic review calculated an overall flare rate (mostly mild flare) of ~25% and a severe flare rate of ~5% 51 . These flare rates were obtained from a meta analysis of 1,842 patients with SLE with 2,751 pregnancies among them, including patients with lupus nephritis 35 and the prospective Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE) study of 385 SLE pregnancies 34 . In the PROMISSE study, 12.7% had a mild or moderate flare and 2.5% had a severe flare at 20 to 23 weeks, plus 9.6% had a mild or moderate flare and 3.0% had a severe flare at 32 to 35 weeks 34 . A single centre observational study 52 , which was not included in the meta analysis 35 , of 398 pregnancies in 304 patients with SLE and 1,045 non pregnant patients with SLE reported an increased flare rate in pregnancy (HR 1.59; 95% CI 1.27-1.96) that was reduced by hydroxychloroquine therapy (HR 1.26; 95% CI 0.88-1.69) in hydroxychloroquine treated patients,
Key points
• various inflammatory rheumatic diseases carry an increased burden of adverse pregnancy outcomes.
• Pregnancy can exacerbate some but not all inflammatory rheumatic diseases.
• Pre-pregnancy counselling is required to evaluate and reduce risks of adverse pregnancy outcomes for each patient.
• Some therapies must be altered before, during and/or after pregnancy.
• Careful monitoring is required throughout pregnancy by a multidisciplinary team.
• vigilance for disease flare is required post-partum.
Cyclophosphamide-induced gonadal toxicity
Gonadal damage induced by cyclophosphamide, leading to reduced ovarian function.
Gestational hypertension
New-onset hypertension presenting after 20 weeks' gestation without significant proteinuria.
Pre-eclampsia
New-onset hypertension presenting after 20 weeks' gestation with significant proteinuria. Indicative of maternoplacental dysfunction.
Small for gestational age
Term used to describe a baby who is smaller than usual for the number of weeks of pregnancy. These babies usually have birthweights below the 10th percentile for gestational age.
www.nature.com/nrrheum compared with HR 1.83 (95% CI 1.34-2.45) in those who were not treated with hydroxychloroquine.
Information on disease activity and pregnancy out comes in women with other inflammatory rheumatic diseases is limited. Some studies show that disease course and severity are not altered by pregnancy in axial spondyloarthritis 53, 54 and similar data are conflicting for PsA 40, 41, 55 .
Presence of autoantibodies. Anti Sjögren syndrome related antigen A (anti SSA)/Ro and anti SSB/La anti bodies are usually detected in patients with SLE and primary Sjögren syndrome, are uncommon in RA and are sometimes detected incidentally in patients who lack other features of autoimmune disease 56 . At around 16 weeks' gestation, these antibodies cross the placen tal barrier by active transplacental transfer (FIG. 1) . This process involves engagement of the Fc region with neo natal Fc receptors on syncytiotrophoblast cells 57 and has a number of implications for the fetus and newborn. The most important risk is that of atrioventricular block (AVB), with congenital complete heart block occurring in 1-2% of babies born to anti SSA/Ro positive mothers with no previously affected pregnancies, known as neo natal lupus syndrome. This risk increases to ~17% if pre vious pregnancies have resulted in AVB 58 . Less common in children born to mothers who are positive for anti SSA/Ro antibodies is late onset cardiomyopathy lead ing to congestive cardiac failure 58 . In three case reports, anti SSA/Ro positivity and anti SSB/La positivity have also been associated with endocardial fibroelastosis, which has a poor cardiac prognosis including end stage heart failure and death and can occur in the absence of AVB 59 .
Other features of neonatal lupus syndrome include a transient subacute cutaneous lupus rash exacerbated by UV exposure after birth, haematological manifestations (such as cytopenia) and hepatobiliary disease 60 . Most of these manifestations resolve in the first 6-9 months of life as maternal anti SSA/Ro antibodies are cleared from the baby's circulation 60 . Persistent positivity for anti phospholipid (aPL) anti bodies identifies individuals at risk of various specific APOs (one or more unexplained deaths of a morpho logically normal fetus at ≥10 weeks' gestation; one or more premature births of a morphologically normal neonate before 34 weeks' gestation because of eclampsia, pre eclampsia, or placental insufficiency; or three or more consecutive spontaneous pregnancy losses at <10 weeks' gestation, unexplained by chromosomal abnormalities or by maternal anatomical or hormonal causes) and maternal thrombosis that characterise antiphospho lipid syndrome (APS) 61, 62 . Common aPL antibodies are detected by lupus anticoagulant, anti cardiolipin and anti β2 glycoprotein 1 assays. Lupus anticoagulant posi tivity seems to be the strongest predictor of APOs in APS 34, 63 and triple positivity for all three tests indicates an especially high risk of pregnancy complications and thrombosis 64, 65 . The presence of aPL antibodies increases the risk of venous thromboembolism in patients with SLE twofold for anticardiolipin positivity and sixfold for lupus anticoagulant positivity, compared with the absence of aPL antibodies 66 . In patients without an underlying autoimmune disease, venous thrombotic risk is increased 1.5fold for anticardiolipin positivity and up to tenfold for lupus anticoagulant positivity 67, 68 , whereas arterial thrombosis is increased threefold and fourfold, respectively 68 . However, these estimates, derived from meta analyses, are limited by a lack of prospective data, small cohort size, lack of controls and variable aPL antibody assay methodology among the source stud ies. Patients with a history of thrombotic APS have a lower live birth rate than those without thrombosis 65 . A 2019 survey of data from the European Registry on Obstetric Antiphospholipid Syndrome 69 , which studied 1,000 women with obstetric APS as defined by the 2006 Sydney classification criteria 61 , has shown that the live birth rate is only 49.6% without treatment, but rises to 85% with the recommended treatment regimen and to 72.4% with other regimens, including low dose aspi rin or low molecularweight heparin (LMWH), but not on the recommended schedule. Recurrent miscarriages were observed before 10 weeks' gestation in 27%, fetal loss in 17% and stillbirth in 18.5% of this cohort of patients with obstetric APS. The survey also reported early pre eclampsia (before 34 weeks' gestation) in 18.1% and early IUGR (before 34 weeks' gestation) in 16.1% of the cases studied 69 .
Presence of organ dysfunction. The presence of organ dysfunction as a complication of an inflammatory rheu matic disease greatly increases the prospect of maternal and fetal morbidity and mortality and should therefore be discussed during pregnancy planning 6, 70 . If a patient has active disease and organ dysfunction, conception should be delayed until a period of disease quiescence and improvement or normalization of organ function is achieved. For example, the presence (or even history) of In women of child-bearing age (per 100,000).
b estimated from aggregated male and female prevalence of 8.4, given that 83% of patients with systemic sclerosis are female.
Endocardial fibroelastosis
a rare heart disorder of infants and children that is characterised by a thickening within the muscular lining of the heart chambers due to an increase in the amount of supporting connective tissue (inelastic collagen) and elastic fibres.
Placental insufficiency
Failure of the placenta to deliver sufficient nutrients and oxygen to the fetus during pregnancy.
active lupus nephritis at conception is a strong predic tor of poor maternal and fetal outcomes 35, 71 . However, the risk associated with renal disease is not specific to patients with rheumatic disease and prospective stud ies involving women with chronic kidney disease of various aetiologies have demonstrated increased risks of pre eclampsia, preterm delivery, small size for gesta tional age and increased infant and perinatal mortality rates [72] [73] [74] . Furthermore, women with advanced chronic kidney disease (stage 4-5) before pregnancy have an increased risk of an accelerated decline in renal func tion, potentially leading to end stage disease and the need for renal replacement therapy either in pregnancy or shortly after 75 . Other relative contraindications to pregnancy in patients with inflammatory rheumatic diseases that require multidisciplinary consultation and management include pulmonary hypertension 76 , severe interstitial lung disease 77 , advanced heart failure 78 and previous severe gestational hypertensive disorders despite therapy 79 .
Medication
Predictive tests to stratify patients at risk of disease relapse and thus requiring intensification rather than withdrawal of therapy in pregnancy are lacking. Therefore, treatment decisions are made on the basis of the pattern of disease activity and manifestations and using standard laboratory markers of disease activity. Medications that are compatible with pregnancy therapy should be continued and intensified appropriately during pregnancy to ensure maintenance of disease control and reduce the risk of APOs (FIG. 2) . The British Society for Rheumatology (BSR) and EULAR have published guidance regarding the use of various anti rheumatic drugs in pregnancy and breastfeeding [7] [8] [9] . Evidence based recommendations are summarized here and in TaBle 2 .
Glucocorticoids. Glucocorticoids can be divided into non fluorinated (such as prednisone, prednisolone, hydrocortisone and methylprednisolone) and fluor inated (such as dexamethasone and betamethasone) formulations. Non fluorinated glucocorticoids are safe in pregnancy and breastfeeding as they are meta bolized in the placenta with less than 10% of the active drug reaching the fetus 80 . Titration to the minimum tolerable dose of corticosteroid is required to reduce complications such as steroid induced diabetes mel litus, hypertension and infections in the mother 81 . Glucocorticoids are associated with an increased risk of premature birth and some reports have suggested that this increased risk is independent of disease activ ity 10, 82 . Some studies in SLE have detected an associa tion between these drugs and premature rupture of the 
Minimum tolerable dose of corticosteroid
The minimum dose required to maintain disease control and reduce complications such as steroid-induced diabetes mellitus, hypertension and infections in the mother.
www.nature.com/nrrheum amniotic sac (known as rupture of membranes) sur rounding the baby 83 , but other studies did not detect this association [84] [85] [86] . Fluorinated corticosteroids are not metabolized by the placenta and cross the placental barrier 87 , so these drugs should be used for fetal indi cations only. Dexamethasone has been suggested to cause developmental problems, such as delayed neu ropsychiatric development 83 , but this conclusion was not confirmed in two other cohorts of children born to antiRo/SSA antibody positive mothers 88, 89 . In preg nancy, non fluorinated corticosteroids are generally administered orally (prednisolone), whereas intravenous administration (for example, with methylprednisolone) is generally used as rescue therapy for severe disease. Compared with prednisolone, parenterally administered methylprednisolone has a prolonged duration of action, with equivalent glucocorticoid (anti inflammatory) effects at a lower dose (80% of prednisolone dose) and similar rates of transplacental transfer 7 . Synthetic DMARDs. A number of conventional syn thetic DMARDs should be stopped before conception. Methotrexate is teratogenic and should be stopped 3 months before conception 7, 9 . Given that leflunomide was teratogenic in animal studies and has a long half life, a cholestyramine washout to eliminate the drug from the body should be completed pre conception, despite reassuring data from accidental exposures in human pregnancies 90 . Mycophenolate mofetil is teratogenic and should be stopped 6 weeks before conception 91 . Cyclophosphamide is teratogenic and should be stopped at least 3 months before conception 92 . Conventional DMARDs that can be continued during pregnancy include hydroxychloroquine, sulfa salazine, azathioprine and the calcineurin inhibitors ciclosporin and tacrolimus 7, 9 . Women who conceive while being treated with leflunomide and then stop this drug and undergo cholestyramine washout in the first trimester 90, 93 , or who are exposed to leflunomide at 
Rescue therapy
Treatment given after a patient has failed to respond to standard therapy.
Nature revIewS | RHEUmATOLOGy various stages of pregnancy without washout 94, 95 , are not at an increased risk of APOs. Although leflunomide does not seem to be a major human teratogen, more data are required before its use during pregnancy can be safely advised.
Targeted synthetic DMARDs (such as apremilast, tofacitinib and baricitinib) are small molecule inhib itors that are increasingly used to treat inflammatory rheumatic diseases [96] [97] [98] . These drugs should be avoided during pregnancy until data are gathered on the risks associated with their use. The precise timing of when to stop these drugs before pregnancy is unclear, but given their short half lives (3-12 h [96] [97] [98] ), stopping each drug 1 month before conception should be sufficient.
Biologic DMARDs. Biologic DMARDs are recombinant proteins, usually either monoclonal IgG1 antibodies or fusion proteins containing the Fc portion of IgG1 joined to receptor blocking proteins. These drugs share similar structure with maternal IgG, which are large proteins (~150 kDa) that are unable to diffuse across the placenta 99 . Active transplacental transfer of mater nal IgG takes place via neonatal Fc receptors on the syncytiotrophoblast [100] [101] [102] and occurs rapidly from week 16 of pregnancy onwards [100] [101] [102] (FIG. 1) . Some biologic DMARDs are fusion proteins containing part or none of the IgG structure, principally etanercept and abatacept. Etanercept is a fusion protein of the soluble TNF recep tor 2 and the Fc region of IgG1a and despite the presence of the Fc region has low rates of transplacental trans fer 103, 104 . Anakinra is a recombinant human IL1 receptor antagonist that does not contain any immunoglobulin structure; hence, it lacks the Fc region and has not been found to cross full term human placenta 105 . Abatacept contains the Fc region of IgG1 fused to the extracellular domain of CTLA4 and has not yet been associated with any specific pattern of risk 106 . Therefore, it is important to consider carefully both the structure and the timing of biologic DMARD exposure during pregnancy.
Current guidelines recommend that patients treated with TNF inhibitors should continue with these drugs through to the second or third trimester (depending on drug bioavailability based on the half life of the drug in the circulation, and depending on transplacental passage based on the structure of the TNF inhibitor). Administration of the TNF inhibitors is usually stopped at appropriate times in pregnancy (TaBle 3) to ensure that there is no TNF inhibitor in the maternal circulation at the time of birth as it would also be present in the baby and persist in the neonatal circulation, possibly putting the baby at risk of infection after administration of live vaccines 7, 9 . If there is a concern that an inflammatory rheumatic disease will flare, TNF inhibitors should be continued throughout pregnancy, but live vaccines, such as rotavirus and tuberculosis, should be avoided in the exposed infant until 6 months of age. This advice is based on a case of fatal tuberculosis like disease reported post BCG vaccination in an infant who was not breast fed but was exposed throughout pregnancy to inflixi mab, a TNF inhibitor with a long half life in infants 107 . Certolizumab pegol, a PEGylated Fabʹ that is specific for TNF, has minimal levels of transfer across the placenta 108 and into breastmilk 109 , and is therefore licenced by the European Medicines Agency and FDA for use during pregnancy and breastfeeding.
Current British and European guidelines recom mend that other biologic DMARDs (such as rituximab, belimumab, anakinra and tocilizumab) are stopped in advance of pregnancy owing to limited data 7, 9 . However, some of these drugs (anakinra and tocilizumab) have been recommended for use during pregnancy if other treatment options are limited and the benefits of main taining disease suppression with these biologic agents outweigh the risks 110, 111 . Increasingly, biosimilars are replacing existing orig inator biologic DMARDs. To date, published evidence on the use of biosimilars in pregnancy is very limited. Given their similarity to originator compounds in terms Medications that are compatible with pregnancy should be continued and intensified appropriately during pregnancy in the case of disease flare. Appropriate treatment depends on the disease and type of manifestation. ±, and/or ; APS, antiphospholipid syndrome; ARD, autoimmune rheumatic disease; IVIG, intravenous immunoglobulins; LMWH, low-molecular-weight heparin; RA , rheumatoid arthritis; SLE, systemic lupus erythematosus.
www.nature.com/nrrheum of identical molecular target and antibody structure, with variation only in post translational modifications (as exists between different batches of existing origina tor biologic DMARDs), it seems reasonable to counsel patients regarding the use of biosimilars in pregnancy on the basis of the existing evidence for each originator compound.
Analgesics. Conventional NSAIDs are generally safe, but should be avoided in the third trimester owing to their effects upon the ductus arteriosus, namely the pre mature closure of this vessel, leading to progressive right heart dysfunction, congestive heart failure and intrauterine death, but can be used with caution in the first trimester owing to a low risk of miscarriage 8 . However, cyclooxygenase2selective NSAIDs are not recommended because of a lack of data and the theo retical risks that these drugs could impair fertilization, implantation and maintenance of pregnancy 112 . Codeine is compatible with pregnancy and during peri conception for acute pain 8 . British Society for Rheumatology guidelines state that no consistent evi dence exists to recommend dose reduction before deliv ery, but neonatologists should be aware of the maternal use of codeine during breastfeeding owing to the risk of central nervous system depression resulting from the unpredictable metabolism of codeine to morphine 8 . Amitriptyline, gabapentin and pregabalin are com monly used to treat chronic pain. Amitriptyline is safe to use during pregnancy, but gabapentin or pregabalin are not recommended 8 .
Co-morbidity medications.
A review of the entire drug list prescribed to each patient is important to ensure that all medications prescribed for co morbidities, particu larly those commonly associated with inflammatory rheumatic diseases, are compatible with pregnancy. In the event of pregnancy, patients with pre existing hypertension should be instructed to switch from angiotensin converting enzyme (ACE) inhibitors, angio tensin II receptor blockers and chlorothiazide agents associated with congenital anomalies to alternative antihypertensive drugs, such as labetalol nifedipine or methyldopa 113 . In addition, women at a moderate or high risk of pre eclampsia should avoid excessive die tary salt intake and should take low dose aspirin 114, 115 . Patients receiving an ACE inhibitor to reduce protein uria before pregnancy may have greater proteinuria as a result of stopping the ACE inhibitor and the increased glomerular filtration rate (of 50-80%) in pregnancy. Even in patients with diabetic nephropathy, this change does not signify worsening renal disease and protein uria often returns to baseline post partum 116 . Warfarin is contraindicated in pregnancy owing to an increased risk of congenital abnormalities if continued after week 6 of gestation; thus, patients taking warfarin should switch to LMWH once pregnancy is confirmed 8 .
Management during pregnancy
General principles. Patients with inflammatory rheu matic diseases who are planning pregnancy or who are pregnant should be managed in a multidisciplinary set ting with close obstetric and rheumatological monitor ing, involving regular clinical, laboratory and obstetric ultrasound evaluations and the advice of other special ists depending on organ involvement. Risk stratification should be performed according to degree and extent of maternal disease in addition to the antibody status of the patient (aPL, anti SSA/Ro and anti SSB/La antibodies). The overall goal is to develop an individualized plan for management to suppress disease activity using a treat totarget approach during pregnancy to optimize the chance of a successful pregnancy outcome (FIG. 3) .
Maintenance and monitoring of disease control.
Disease control is maintained by continued prescrip tion of medications that are compatible with pregnancy. For patients with inflammatory arthritis, sulfasalazine and hydroxychloroquine are ideal maintenance thera pies 7, 9 and, with the caveats already discussed, biologic DMARDs might be considered. In patients with SLE, hydroxychloroquine is a mainstay of treatment and dis continuation of this drug is associated with an increased risk of flares and APOs in pregnancy 15, 16, 52 . Other 
Ductus arteriosus
a blood vessel in the fetus connecting the main pulmonary artery to the proximal descending aorta, allowing most blood from the right ventricle to bypass the lungs. Premature closure of this blood vessel leads to progressive right heart dysfunction, congestive heart failure and intrauterine death.
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suitable DMARDs include azathioprine, ciclosporin and tacrolimus 7, 9 . Glucocorticoids can be used to treat any inflam matory rheumatic disease, particularly to treat disease flares, and should be titrated to the minimum tolera ble dose to maintain disease control and limit steroid related adverse effects such as hyperglycaemia and bone loss 17, 81 . Concomitant use of calcium and vitamin D until the end of lactation is also particularly important for patients treated with glucocorticoids and/or hepa rin as they are at increased risk of osteoporosis 17, 117 . All pregnant patients with SLE at high risk of pre eclampsia, including those with lupus nephritis or who are posi tive for aPL antibodies, should be treated with low dose aspirin (≤150 mg daily), which has been shown to reduce the risk of pre eclampsia in non SLE high risk pregnancies 17, 118 . When monitoring disease activity in pregnancy, awareness of physiological changes of pregnancy that resemble those of disease flare is important. Examples of such changes include proteinuria (up to 300 mg per day), increased erythrocyte sedimentation rate (up to 70 mm/h), a 2-3fold rise in serum complement concen trations or a fall in serum haemoglobin concentrations (<110 g/l) 119 . In addition, increasing degrees of back pain and swelling of the hands, feet and knees are common in late pregnancy and could be mistaken for arthritis flare. Therefore, C reactive protein is a more accurate indica tor of inflammation than erythrocyte sedimentation rate in pregnancy 119 and should be used in this situation for monitoring, except in SLE for which any fall in comple ment (C3 or C4) of ≥25% is important, even if into the 'normal' range 17 . For most inflammatory rheumatic diseases, the same outcome assessment as for non pregnant patients is used during pregnancy, but modified disease activity scores are recommended in some conditions. For example, a modified 28joint disease activity score for RA includes a measure of C reactive protein (DAS28CRP) and unlike the standard DAS28 lacks the global health score, which can be affected by pregnancy itself 45 . Owing to the com plexity of SLE assessment in pregnancy, a disease activity index has been developed and validated by modifying the British Isles Lupus Assessment Group (BILAG2004) to create the BILAG2004Pregnancy index so that physiological changes of pregnancy do not influence the score 120 .
Monitoring for pregnancy complications. Women with inflammatory rheumatic diseases should seek antena tal care early (before 12 weeks of pregnancy) and this care should be managed in a multidisciplinary setting. In addition to routine pregnancy monitoring, clinical assessment of the mother and the baby should include measurement of blood pressure, urinalysis and blood tests, such as for autoantibody status and disease activ ity. In addition, obstetric ultrasound scans are required at specified intervals to record fetal anatomy, growth and development as recommended for healthy pregnancy with additional monitoring in the third trimester for SLE and APS pregnancies 17, 69 .
Prevention and treatment of pre-eclampsia. There is an increased risk of pre eclampsia in patients with inflam matory rheumatic diseases, particularly in patients with SLE, previous renal disease or patients treated with concomitant glucocorticoids 14, 17, [33] [34] [35] [36] . Risk factors for pre eclampsia and APOs in SLE pregnancy include a high level of disease activity at conception and during preg nancy, a history of lupus nephritis, maternal hyperten sion, presence of aPL antibodies, low serum complement concentrations and thrombocytopenia 121 . All patients at increased risk of pre eclampsia should be treated with low dose aspirin until delivery 17, 51 . In addition, they should be monitored for development of pre eclampsia, which includes measurement of blood pressure and proteinuria at each visit and fetal ultrasound and uterine artery Doppler ultrasound flow studies, as ordered by obstetric consultants. The presence of bilateral uterine notching, indicating abnormal blood flow, between 23 and 25 weeks' gestation can be used to predict early onset pre eclampsia and gestational hypertension 122 . In addition, measurement of circulating angiogenic factors (including soluble Fms liketyrosine kinase 1, placental growth factor and soluble endoglin), which are dysregulated in pre eclampsia in non autoimmune pregnancies 123 , can also be used to predict the risk of various APOs, including pre eclampsia in patients with SLE 124 . First line treatment of hypertension in pregnancy is labetalol, with alternatives being methyldopa and nifed ipine; ACE inhibitors, angiotensin II receptor block ers and chlorothiazide diuretics are associated with congenital malformations 125 . Distinguishing between lupus nephritis and pre eclampsia is challenging but important, as the manage ment of each condition is different 126 . Both conditions are characterized by proteinuria, oedema, renal impair ment, hypertension and thrombocytopenia. Indicators of lupus nephritis include C3 and C4 levels that are falling (or failing to increase), a rising titre of antibodies specific for double stranded DNA, active urinary sediment and other clinical indicators of SLE activity, such as skin dis ease, arthritis and cytopenia 126 . Anti C1q antibodies are also associated with renal involvement in SLE 127 and may therefore function as a biomarker of active SLE. By con trast, many of these features are lacking in pre eclampsia and unlike lupus nephritis, in pre eclampsia, C3 and C4 levels often increase 126 . If these tests are indecisive a renal biopsy is required to differentiate between lupus
Uterine artery Doppler ultrasound
a technique used to measure uterine artery blood flow between mother and baby. nephritis and pre eclampsia. Depending on the clinical circumstances and the gestation of the pregnancy, pre mature delivery of the fetus may be mandated, as the only cure for pre eclampsia is delivery of the baby and potent immunosuppression cannot be given for serious renal lupus flare until after delivery owing to the increased risk of adverse events that would affect the mother and baby in this situation. Multidisciplinary care is critical in this situation as inappropriate management could result in the death of the baby and/or mother 118, 128 .
Thromboprophylaxis and anticoagulation.
Pregnancy itself is a pro coagulant state with alterations in both coagulation and fibrinolysis, presumably to reduce blood loss at delivery 119 , and this procoagulant risk is increased in various inflammatory rheumatic diseases 129 , particu larly APS 61, 63, 69 . Thromboprophylaxis is required with thera peutic anticoagulation in APS and is a consideration with anti platelet therapy in other conditions, principally SLE 17, 63, 69 . Treatment to prevent recurrent early miscarri age is the only management in obstetric APS supported by clinical trial data 63, 69 . Dual treatment with low dose aspirin and LMWH is the standard ofcare for all patients with APS. Warfarin is contraindicated in preg nancy owing to its teratogenic effects and patients being treated with this anticoagulant drug should be switched to a therapeutic dose of LMWH once pregnancy is con firmed 8 . Evidence is lacking regarding the safety of the direct oral anticoagulants apixaban, rivaroxaban, dab igatran and fondaparinux in pregnancy and use of these drugs is therefore not recommended 130 .
Anti-SSA/Ro and anti-SSB/La complications. Using fetal cardiac ultrasound, screening for congenital heart block in pregnancies of anti SSA/Ro positive and/or anti SSB/ La positive mothers with a previously affected child should begin at week 16 of pregnancy 17 . For anti SSA/ Ro positive and/or anti SSB/La positive women with no previous congenital heart block, most fetal cardiol ogists recommend an initial fetal cardiac ultrasound scan at 16-20 weeks with a repeat at 28 weeks if the ini tial scan is normal. Once established, complete AVB is irreversible and cardiac pacing is almost always required, but specialist management of any associated cardiac disease may improve fetal outcome 131 . Fluorinated gluco corticoids have been used to treat the early stages of AVB 132 , but the benefit of this therapy has not been proven. Hydroxychloroquine, however, is associated with a reduction in the rate of recurrent AVB in future pregnancies after an affected pregnancy 133 and a lower rate of AVB in babies born to mothers with anti SSA/Ro antibodies with or without SLE 134, 135 . Non cardiac neo natal lupus manifestations are transient 136 and specific treatment is not required.
Management of flares and organ dysfunction.
Standard management of inflammatory rheumatic dis ease flares in pregnancy is to treat with systemic gluco corticoids and add other DMARDs depending upon the disease and type of manifestation (FIG. 2) . In inflamma tory arthritis, addition of sulfasalazine and/or hydroxy chloroquine is suitable to maintain disease control 7, 9 .
For connective tissue disease or vasculitis, azathioprine is preferred 7, 9 and in the case of lupus nephritis or cyto penia, tacrolimus can be used alone or in combination with glucocorticoids and/or other DMARDs in pregnancy 137 .
In the case of severe maternal inflammatory rheumatic disease, intravenous immunoglobulins and plasma exchange may be therapeutic 138, 139 ; premature delivery of the fetus should also be considered, to reduce the adverse consequences of chronic intrauterine asphyxia that can arise from impaired placental function caused by maternal disease 140 .
Chorionic villi
Clinical review • Aim to achieve disease remission for at least 4 For patients with inflammatory rheumatic diseases, the chance of a successful pregnancy outcome is optimized by the development of an individualized plan to suppress disease activity using a treatto-target approach. Patients who are planning pregnancy or who are pregnant should be managed in a multidisciplinary setting with close obstetric and rheumatological monitoring, with risk stratification according to the degree and extent of maternal disease as well as the antibody status of the patient. Anti-SSA , anti-Sjögren syndrome-related antigen A ; APS, antiphospholipid syndrome; AVB, atrioventricular block; SLE, systemic lupus erythematosus.
Thromboprophylaxis
In this context, the prevention of thromboembolic disease by pharmacological means.
Fetal cardiac ultrasound
Technique used to evaluate the structure of the fetal heart.
Screening for congenital heart block
The use of fetal cardiac ultrasound at the 16th to 20th week of pregnancy in anti-SSa/ Ro-positive mothers.
Cardiac pacing
Technique used to regulate heart rate involving the fitting of a pacemaker.
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Post-partum management Risk of post-partum flare. Post partum inflammatory rheumatic disease flares are common but vary con siderably in severity and timing, from several days to 3-6 months after delivery 45, 46, 52, 54 . Evidence that increas ing the dose of glucocorticoids prevents flare does not exist, but it is possible that flares are worsened by patients discontinuing therapy for fear of harming their baby when breastfeeding.
Drugs and breastfeeding.
Drugs that can be used in pregnancy are usually compatible with breastfeeding, but few trials have tested this compatibility (TaBle 4) . Certolizumab pegol is the only TNF inhibitor licensed by the European Medicines Agency and FDA for use dur ing breastfeeding as it has minimal transfer into breast milk 109 . Most inflammatory rheumatic disease flares during breastfeeding are treated by starting or increas ing the dose of existing oral prednisolone or intramus cular methylprednisolone 126 . Hydroxychloroquine is compatible with pregnancy and, although it enters the breast milk 7, 9, 141 , evidence does not exist that this drug can harm the baby. Similarly, sulfasalazine is commonly used by mothers with various inflammatory condi tions. However, 5 mg daily folic acid should be taken during pregnancy and breastfeeding to prevent folate deficiency in the baby 7 . Patients treated with LMWH in pregnancy should continue this drug for 6 weeks post partum 142 and patients previously taking warfarin can re start this drug during breastfeeding 8, 142 The safety of the direct oral anticoagulants (such as apixaban, riva roxaban, dabigatran and fondaparinux) during breast feeding is unknown and these drugs are therefore not recommended during breastfeeding 130 .
Contraception. Contraception should be discussed soon after delivery for women with inflammatory rheumatic diseases and at risk of post partum flare to ensure that they do not have a further pregnancy that is unplanned 17 . Many women still think that breastfeeding protects them from further pregnancy. The most appropriate contra ception method is probably the method they used before pregnancy. An intrauterine device, such as a hormone releasing coil, is a viable and safe option for a patient to consider and discuss with their general practitioner. Risk of infection is low in women using intrauterine devices and DMARDs, except in individuals whose behaviour, independent of their disease and its treatment, puts them at increased risk.
Conclusions
Pregnancy in patients with inflammatory rheumatic diseases has the best outcomes if women conceive dur ing disease remission and with appropriate therapy. Persistent disease activity and disease flares in pregnancy are associated with an increased risk of IUGR, resulting in babies that are small for gestational age and premature delivery. During pregnancy, screening and managing active disease and the increased risk of pre eclampsia are impor tant, particularly in patients with a history of hypertension, RA or SLE (especially lupus nephritis and APS). Women with inflammatory rheumatic diseases require specific advice about drug therapy while trying to conceive, during pregnancy and while breastfeeding and should be aware of the risk of post partum flares. However, with careful planning, monitoring and treatment, most women with these diseases can have successful pregnancies. 
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